《大行報告》大和削泰格醫藥(03347.HK)目標價至89元 評級「跑贏大市」
大和發表研究報告指,泰格醫藥(03347.HK)中期收入按年增長近75%,若撇除疫情相關銷售,則第二季及上半年收入增長40%及45%,表現較該行早前預期優異。
大和因此將泰格醫藥2022至2024年純利預測上調46%至82%,以反映自去年起公司業績表現強勁。不過,該行亦指出,上半年泰格的毛利率按年下跌7.5個百分點,純利潤率更大跌逾28個百分點,主要歸因於印尼COVID相關臨床項目的患者招募增加所帶來的額外轉嫁費用。
該行指,公司在充滿挑戰的環境中,計劃將經營重心轉移到利潤更高的領域,相信業務轉型需要一段時間才能提高盈利能力,將目標價由170元大削至89元,對應預測今明兩年綜合市盈率倍數由91倍降至25倍,但維持「跑贏大市」評級不變。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.